Premium
Oral cobalamin (vitamin B 12 ) treatment. An update
Author(s) -
ANDRÈS E.,
DALIYOUCEF N.,
VOGEL T.,
SERRAJ K.,
ZIMMER J.
Publication year - 2009
Publication title -
international journal of laboratory hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.705
H-Index - 55
eISSN - 1751-553X
pISSN - 1751-5521
DOI - 10.1111/j.1751-553x.2008.01115.x
Subject(s) - cobalamin , malabsorption , pernicious anemia , medicine , vitamin b12 , gastroenterology , megaloblastic anemia , prospective cohort study , anemia , pediatrics
Summary The objective of this review was to evaluate oral cobalamin (vitamin B 12 ) therapy in adult and elderly patients, from the perspective of a hematologist. PubMed was systematically searched for English and French articles published from January 1990 to January 2007. Data from our working group, the ‘ Groupe d’étude des carences en vitamine B 12 des Hôpitaux Universitaires de Strasbourg ’, have also been included. Several prospective studies in well‐determined population ( n = 4), prospective randomized studies ( n = 3) and a systematic review by the Cochrane group ( n = 1) provide evidence that oral cobalamin therapy may adequately treat cobalamin deficiency, particularly hematological abnormalities or manifestations. These studies suggest that at least 1000 μ g/day of oral cyanocobalmin are needed for pernicious anemia and a mean daily dose of 250 μ g for food‐cobalamin malabsorption. This present review confirms the previously reported efficacy of oral cobalamin treatment in adult and elderly patients.